Article Details

Dosing of TI-3000 pDNA Vaccine Begins in Phase 1 Merkel Cell Carcinoma Trial

Retrieved on: 2022-07-26 01:07:21

Tags for this article:

Click the tags to see associated articles and topics

Dosing of TI-3000 pDNA Vaccine Begins in Phase 1 Merkel Cell Carcinoma Trial. View article details on hiswai:

Excerpt

Sponsor: Immunomic Therapeutics, Inc. Recruitment Contact: Veronica Gonzalez 1-301-968-3501 vgonzalez@immunomix.com.

Article found on: www.targetedonc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up